{ "docId": "019de517-1302-72c9-b1b1-402f68725e8a", "docSlug": "8240d0b9060d59c07a4e5f5063c97322", "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides", "authorId": "adagio-therapeutics", "authorName": "Invivyd", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "pageCount": 11, "prevPage": 1, "nextPage": 3, "slideType": "disclaimer", "function": "front_matter", "density": "balanced", "nDataPoints": 0, "notes": null, "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/2", "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json", "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-2", "components": [ { "bbox": { "h": 0.609, "w": 0.91, "x": 0.045, "y": 0.204 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"seek,\" \"could,\" \"intend,\" \"target,\" \"aim,\" \"project,\" \"designed to,\" \"estimate,\" \"believe,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, the progress and timing of our ongoing research and clinical development activities, including with respect to VYD222; the timing of anticipated initial primary endpoint data from our CANOPY Phase 3 pivotal clinical trial; our expectation to rapidly generate clinical data for a potential VYD222 emergency use authorization (EUA) submission; our plans to submit an application for EUA in the U.S. as soon as practicable; whether we are able to successfully submit an EUA in the future, and the outcome of any such EUA submission; the company's expectations regarding the size of target patient populations and the potential market opportunity for its product candidates; the potential of the company's INVYMAB platform approach to rapidly, serially generate new antibodies to address viral threats; our beliefs regarding the need of immunocompromised people for additional therapeutic options to protect against COVID-19; the future of the COVID-19 landscape; our expectations regarding the size of target patient populations and the potential market opportunity for our product candidates, as well as our market position; the CANOPY clinical trial design; the potential commercialization of VYD222 in the U.S., if authorized; our belief that our existing cash resources will be sufficient to support an expected cash runway into the fourth quarter of 2024; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing and progress of our discovery, preclinical and clinical development activities; our ability to rapidly generate the data needed from the CANOPY clinical trial to support a potential EUA submission for VYD222; whether we are able to successfully submit an EUA in the future, and the outcome of any such EUA submission; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of VYD222 or other product candidates based on neutralizing activity in preclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; the risk that results of preclinical studies or clinical trials may not be predictive of future results in connection with current or future clinical trials; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether our platform approach enables us to rapidly, serially generate new antibodies to address viral threats; whether VYD222 or any other product candidate is able to demonstrate and sustain neutralizing activity against predominant SARS-CoV-2 variants, particularly in the face of viral evolution; and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading \"Risk Factors\" in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0acdefa9-d450-4f82-b98d-532325c8c3e4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.036, "w": 0.869, "x": 0.045, "y": 0.84 }, "kind": "source-note", "text": "© 2023 Invivyd, Inc. Invivyd, Invymab and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "083b4716-0a0d-4043-b26a-d9af846b00e4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.105, "w": 0.72, "x": 0.045, "y": 0.049 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d02109ee-4bcd-4b16-bd35-9d74b6266e0a", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 3, "from": 1, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "70ae55fa-de1b-4bab-93c4-6903f1924753", "evidence": "The presentation provides an overview of the current situation and the urgency of the need", "position": 1, "objective": "Why is now the right time for VYD222?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }